NewAmsterdam Pharma Surges 8.1% on Breakthrough Trial Results and Earnings Optimism

Summary
• NewAmsterdam Pharma (NAMS) rockets 8.1% intraday, hitting $24.82 amid Phase 3 trial success for obicetrapib.
• 2Q 2025 results show 57% revenue growth and a 56% narrower net loss, signaling operational improvement.
• Analysts highlight insider buying and Buy ratings as tailwinds for the 8.3% weekly rally.

NewAmsterdam Pharma’s stock has ignited a sharp intraday rally, surging 8.1% to $24.82 as positive Phase 3 trial data and narrowing losses drive momentum. The biotech sector remains in focus as the stock trades near its 52-week high of $27.29, with technical indicators and options activity suggesting sustained bullish sentiment.

Phase 3 Trial Success and Earnings Optimism Drive NAMS Surge
NewAmsterdam Pharma’s 8.1% intraday surge is fueled by two catalysts: positive Phase 3 trial results for obicetrapib, its CETP inhibitor targeting cardiovascular and neurodegenerative diseases, and improved 2Q 2025 earnings. The trial data, which demonstrated robust LDL-C reduction, has drawn Buy ratings from analysts, while the company’s 57% revenue growth and 56% narrower net loss compared to 2Q 2024 underscore its improving financial health. Insider buying and a 52-week high Relative Strength (RS) rating of 86 further amplify market confidence, positioning NAMS as a short-term outperformer in a volatile biotech landscape.

Options and Technicals: Capitalizing on NAMS’ Bullish Momentum
• MACD: 0.604 (above signal line 0.706), RSI: 54.81 (neutral), 200D MA: $20.88 (below price).
• Bollinger Bands: Price at $24.82 (above upper band $24.23), suggesting overbought conditions.

Top Options Picks:
• NAMS20251121C22.5 (Call, $22.5 strike, 2025-11-21):
- IV: 38.39% (moderate), Leverage Ratio: 7.09%, Delta: 0.7377 (high sensitivity), Theta: -0.0138 (moderate decay), Gamma: 0.0635 (strong price sensitivity).
- Payoff: At 5% upside (target $26.06), payoff = $3.56 per contract. This call offers high leverage and gamma to capitalize on continued bullish momentum.
• NAMS20251121C25 (Call, $25 strike, 2025-11-21):
- IV: 63.05% (elevated), Leverage Ratio: 7.30%, Delta: 0.5731 (moderate), Theta: -0.0199 (accelerated decay), Gamma: 0.0465 (responsive to price swings).
- Payoff: At 5% upside, payoff = $1.06 per contract. This option balances risk and reward, ideal for a breakout above $25.85 (intraday high).

Trading Setup: Key support at $21.63 (30D) and resistance at $23.33 (200D). A break above $25.85 could trigger a retest of the 52-week high. Aggressive bulls may consider NAMS20251121C22.5 into a bounce above $24.23 (Bollinger upper band), while conservative traders might target NAMS20251121C25 for a measured move. High gamma and moderate IV in both contracts make them suitable for short-term directional bets.

Backtest NewAmsterdam Pharma Stock Performance
The backtest of NAMS's performance after an intraday surge of 8% shows favorable results, with win rates and returns indicating positive short-to-medium-term gains. The 3-Day win rate is 48.92%, the 10-Day win rate is 51.38%, and the 30-Day win rate is 56.00%, suggesting that NAMS tends to perform well in the immediate aftermath of such events. The maximum return observed was 12.18% over 30 days, which implies that there is potential for significant gains following an intraday surge.

NAMS’ Rally Gains Legs: Watch 52-Week High for Confirmation
NewAmsterdam Pharma’s 8.1% surge reflects a confluence of trial success, earnings optimism, and technical strength. The stock’s proximity to its 52-week high of $27.29 and elevated gamma in key options contracts suggest momentum traders are positioning for a breakout. With Amgen (AMGN) leading the biotech sector at +0.46%, NAMS’ ability to sustain above $24.23 (Bollinger upper band) will be critical. Investors should monitor the $25.85 intraday high as a near-term pivot point—clearing this level could validate a broader bullish case, while a pullback to $21.63 (30D support) may offer a second entry. For now, the NAMS20251121C22.5 and NAMS20251121C25 options remain top picks for capitalizing on this high-conviction trade.